MyMedR

Displaying all 5 publications

Abstract:

Sort:

Fulltext Magnetic/Polyetherimide-Acrylonitrile Composite Nanofibers for Nickel Ion Removal from Aqueous Solution

Aijaz MO, Karim MR, Alharbi HF, Alharthi NH, Al-Mubaddel FS, Abdo HS

Membranes (Basel), 2021 Jan 12;11(1).
PMID: 33445745 DOI: 10.3390/membranes11010050

In this study, a magnetic/polyetherimide-acrylonitrile composite nanofiber membrane with effective adsorption of nickel ions in an aqueous solution was created using a simple electrospinning method. Iron oxide nanoparticles (NPs) were stirred and ultrasonically dispersed into a polyetherimide-acrylonitrile solution to create a homogenous NPs suspension, which was placed in an electrospinning machine to produce a uniform and smooth nanofiber composite membrane. Nanoparticle incorporation into this membrane was confirmed using scanning electron microscope, energy dispersive X-ray spectroscopy (EDX), Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and NPs aqueous stability from a leaching test. The high adsorption capability of the membrane on nickel ions was attributed to the combination of magnetic NPs, polyetherimide-acrylonitrile matrix, and the nanostructure of the membrane. A membrane containing magnetic NPs demonstrated the maximum adsorption capabilities (102 mg/g) of nickel ions in an aqueous solution. Various kinetic and isotherm models were applied to understand the adsorption behavior, such as pseudo-second-order kinetic and Langmuir isotherm models. A polyetherimide-acrylonitrile composite nanofiber membrane containing magnetic NPs could be used as an environmentally friendly and nontoxic adsorbent for the removal of nickel ions in an aqueous medium due to its ease of preparation and use and stability in aqueous mediums.
Fulltext WS2: A New Window Layer Material for Solar Cell Application

Bin Rafiq MKS, Amin N, Alharbi HF, Luqman M, Ayob A, Alharthi YS, et al.

Sci Rep, 2020 Jan 21;10(1):771.
PMID: 31964954 DOI: 10.1038/s41598-020-57596-5

Radio frequency (RF) magnetron sputtering was used to deposit tungsten disulfide (WS2) thin films on top of soda lime glass substrates. The deposition power of RF magnetron sputtering varied at 50, 100, 150, 200, and 250 W to investigate the impact on film characteristics and determine the optimized conditions for suitable application in thin-film solar cells. Morphological, structural, and opto-electronic properties of as-grown films were investigated and analyzed for different deposition powers. All the WS2 films exhibited granular morphology and consisted of a rhombohedral phase with a strong preferential orientation toward the (101) crystal plane. Polycrystalline ultra-thin WS2 films with bandgap of 2.2 eV, carrier concentration of 1.01 × 1019 cm-3, and resistivity of 0.135 Ω-cm were successfully achieved at RF deposition power of 200 W. The optimized WS2 thin film was successfully incorporated as a window layer for the first time in CdTe/WS2 solar cell. Initial investigations revealed that the newly incorporated WS2 window layer in CdTe solar cell demonstrated photovoltaic conversion efficiency of 1.2% with Voc of 379 mV, Jsc of 11.5 mA/cm2, and FF of 27.1%. This study paves the way for WS2 thin film as a potential window layer to be used in thin-film solar cells.
Fulltext A cross sectional study: the knowledge, attitude, perception, misconception and views (KAPMV) of adult family members of people living with human immune virus-HIV acquired immune deficiency syndrome-AIDS (PLWHA)

Bhagavathula AS, Bandari DK, Elnour AA, Ahmad A, Khan MU, Baraka M, et al.

Springerplus, 2015;4:769.
PMID: 26688783 DOI: 10.1186/s40064-015-1541-2

We intended to assess knowledge, attitude, perception, misconception and views (KAP-MV) of family members of PLWHA. A cross-sectional retrospective study conducted in Anti-retroviral centre of Mahatma Gandhi Memorial-MGM hospital, Warangal, Telangana, South-India from July to September 2014. A questionnaire containing 41 items was distributed among adult family members accompanying patients living with HIV/AIDS-PLWHA. Level of KAP-MV was categorized into poor (0-28), average (29-55) and good (56-82). Analysis was performed by Pearson's Chi square, analysis of variance and Spearman's correlation test on 41 variables using SPSS version 21 and p
Contemporary application of microbubble technology in water treatment

Nair SS, Pinedo-Cuenca R, Stubbs T, Davis SJ, Ganesan PB, Hamad F

Water Sci Technol, 2022 Nov;86(9):2138-2156.
PMID: 36378171 DOI: 10.2166/wst.2022.328

Microbubble (MB) technology constitutes a suite of promising low-cost technologies with potential applications in various sectors. Microbubbles (MBs) are tiny gas bubbles with diameters in the micrometre range of 10-100 μm. Along with their small size, they share special characteristics like slow buoyancy, large gas-liquid interfacial area and high mass-transfer efficiency. Initially, the review examines the key dissimilarities among the different types of microbubble generators (MBG) towards economic large-scale production of MBs. The applications of MBs to explore their effectiveness at different stages of wastewater treatment extending from aeration, separation/ flotation, ozonation, disinfection and other processes are investigated. A summary of the recent advances of MBs in real and synthetic wastewater treatment, existing research gaps, and limitations in upscaling of the technology, conclusion and future recommendations is detailed. A critical analysis of the energetics and treatment cost of combined approaches of MB technology with other advanced oxidation processes (AOPs) is carried out highlighting the potential applicability of hybrid technology in large-scale wastewater treatment.
Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction

Hamad F, Elnour AA, Elamin A, Mohamed S, Yousif I, Don J, et al.

Curr Diabetes Rev, 2021;17(3):280-292.
PMID: 32867644 DOI: 10.2174/1573399816999200821164129

BACKGROUND: The major cardiovascular outcome trials on glucagon-like peptide one-receptor agonists have examined its effect on hospitalization of subjects with heart failure; however, very limited trials have been conducted on subjects with reduced left ventricular ejection fraction (r- LVEF) as a primary outcome.
OBJECTIVE: We have conducted a systematic review of two major (FIGHT and LIVE) placebo-controlled trials of liraglutide and its clinical effect on the ejection fraction of subjects with heart failure.
METHODS: Medline data was retrieved for trials involving liraglutide from 2012 to 2020. The inclusion criteria for trials were: subjects with or without type 2 diabetes mellitus (T2DM), subjects with heart failure with rLVEF, major trials (phase II or III) on liraglutide, trials included liraglutide with defined efficacy primary outcome of patients with heart failure with rLVEF. The search was limited to the English language, whereby two trials [FIGHT and LIVE] had been included and two trials were excluded due to different primary outcomes. Participants (541) had been randomized for either liraglutide or placebo for 24 weeks.
RESULTS: In the FIGHT trial the primary intention-to-treat, sensitivity, and diabetes subgroup analyses have shown no significant between-group difference in the global rank scores (mean rank of 146 in the liraglutide group versus 156 in the placebo group; Wilcoxon rank-sum P=.31), number of deaths, re-hospitalizations for heart failure, or the composite of death or change in NT-pro BNP level (P= .94). In the LIVE trial, the change in the left ventricular ejection fraction (LVEF) from baseline to week 24 was not significantly different between treatment groups. The overall discontinuation rate of liraglutide was high in the FIGHT trial (29%, 86) as compared to that in the LIVE trial (11.6%, 28).
CONCLUSION: FIGHT and LIVE trials have demonstrated that liraglutide use in subjects with heart failure and rLVEF was implicated with an increased adverse risk of heart failure-related outcomes.